Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)

Overview

cited authors

Portales, F., Philip, P. A., Hammel, P., Buscaglia, M., Pazo-Cid, R., Manzano Mozo, J. L., Kim, E. S., Dowden, S., Zakari, A., Borg, C., Terrebonne, E., Rivera Herrero, F., Li, J. Shiansong, Ong, T. J., Nydam, T., Lacy, J.

funding text

Celgene Corporation

authors

Zakari, Ahmed, MD

Publication Date

September 1, 2017

webpage

Web of Science

published in

ANNALS OF ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.